慢性乙型肝炎患者外周血CD8+CD28+T淋巴细胞百分比的变化及其临床意义探讨

doi:10.3969/j.issn.1672-5069.2019.02.007

Abstract

Abstract: Objective To investigate the changes of peripheral blood CD8⁺CD28⁺T lymphocyte percentages in patients with hepatitis B. Methods A total of 88 patients with hepatitis B and 20 healthy individuals were recruited in 902nd hospital of PLA between April 2018 and August 2018,and the patients with hepatitis B included patients in immune tolerance phase（n=20）,immune clearance phase（n=28）,low replication phase （n=20）,and re-activation phase（n=20）. The percentages of CD8⁺CD28⁺T lymphocytes in peripheral blood were measured by flow cytometry. Results The percentages of CD8⁺CD28⁺T lymphocytes in patients in immune tolerance phase were（26.3±3.4）%,not significantly different as compared to（26.1±3.5）% in healthy persons（P>0.05）;the percentages of CD8⁺CD28⁺T lymphocytes in patients in immune clearance were（40.1±4.7）%,significantly higher than that in healthy control（P<0.05）;the percentages of CD8⁺CD28⁺T lymphocytes in patients inactive phase and reactive stage were （20.3±2.2）% and （26.1±2.2）%,respectively,significantly lower than that in healthy control （P<0.05）;the CD8⁺CD28⁺T lymphocytes in patients with high,moderate and low serum HBsAg level were（24.0±7.5）%,（28.4±8.9）% and （33.2±8.5）%,respectively,with statistically significant differences among them （P<0.05）. Conclusion s There are significant differences in the percentages of peripheral blood CD8⁺CD28⁺T lymphocytes in patients with hepatitis B at different immune phases,which might be related to the dysfunctions of immune system activated by the viral infection.

Key words: Hepatitis B, Immune stage, Hepatitis B surface antigen, CD8⁺CD28⁺T lymphocytes

Zhou Jiyun, Ma Yong, Ding Tilong, Tu Yuanhang, Chen Ce. Changes of peripheral blood CD8⁺CD28⁺T lymphocyte percentages in patients with hepatitis B[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 180-183.

References

[1] MacLachlan JH,Locarnini S,Cowie BC. Estimating the global prevalence of hepatitis B. Lancet,2015,386(10003):1515-1517.
[2] Chen P,Yu C,Ruan B,et al.Prevalence of hepatitis B in insular regions of southeast China:a community-based study. PLoS One,2013,8(2):e56444.
[3] Hong MZ,Huang WQ,Min F,et al.Enhanced HBsAg synthesis correlates with increased severity of fibrosis in chronic hepatitis B patients. PLoS One,2014,9(1):e87344.
[4] Bertoletti A,Maini M,Williams R.Role of hepatitis B virus specific cytotoxic T cells in liver damage and viral control. Antiviral Res,2003,60(2):61-66.
[5] 秦浩歌,颜迎春,吴晓枫,等. 慢性乙型肝炎患者和无症状病毒携带者外周血B淋巴细胞亚群的变化. 中华肝脏病杂志,2006,14(10):773-774.
[6] 张建春,翁锡定,陈孙云,等. 乙型肝炎患者外周血T淋巴细胞亚群的变化. 实用肝脏病杂志,2013,15(4):356-357.
[7] Evans EJ,Esnouf RM,Manso-Sancho R,et al.Crystal structure of a soluble CD28-Fab complex. Nat Immunol,2005,6(3):271-279.
[8] Liang Y,Cucchetti M,Roncagalli R,et al.The lymphoid lineage-specific actin-uncapping protein Rltpr is essential for costimulation via CD28 and the development of regulatory T cells. Nat Immunol,2013,14(8):858-866.
[9] 张泉,邱思芳,赵逵,等. 结直肠癌及腺瘤患者CD4+、CD8+和CD28+T淋巴细胞的亚群变化及临床意义. 中国癌症杂志,2018,28(8):577-583.
[10] Ndlovu H,Darby M,Froelich M,et al.Inducible deletion of CD28 prior to secondary nippostrongylus brasiliensis infection impairs worm expulsion and recall of protective memory CD4(+) T cell responses. PLoS Pathog,2014,10(2):e1003906.
[11] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2015年版).实用肝脏病杂志,2016,19(3):Ⅴ-ⅩⅩⅢ.
[12] Jenkins MK,Ashwell JD,Schwartz RH.Allogeneic non-T spleen cells restore the responsiveness of normal T cell clones stimulated with antigen and chemically modified antigen-presenting cells. J Immunol,1988,140(10):3324-3330.
[13] Mueller DL,Jenkins MK,Schwartz RH.An accessory cell-derived costimulatory signal acts independently of protein kinase C activation to allow T cell proliferation and prevent the induction of unresponsiveness. J Immunol,1989,142(8):2617-2628.
[14] Bruss V.Envelopment of the hepatitis B virus nucleocapsid. Virus Res,2004,106(2):199-209.
[15] Uzun L,Say R,Unal S,et al.Hepatitis B surface antibody purification with hepatitis B surface antibody imprinted poly(hydroxyethyl methacrylate-N-methacryloyl-L-tyrosine methyl ester) particles. J Chromatogr Analyt Biomed Lif Sci,2009,877(3):181-188.
[16] Assrir N,Soussan P,Kremsdorf D,et al.Role of the hepatitis B virus proteins in pro-and anti-apoptotic processes. Front Biosci (Landmark Ed),2010,15:12-24.
[17] Liaw YF.Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int,2009,29(S1):100-107.
[18] Lenschow DJ,Zeng Y,Thistlethwaite JR,et al.Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. Science,1992,257(5071):789-792.
[19] Zhang S,Guo H,Smith R.Dynamical analysis for a hepatitis B transmission model with immigration and infection age. Math Biosci Eng,2018,15(6):1291-1313.
[20] Pandey A,Ezemenari S,Liaukovich M,et al.A Rare Case of Pembrolizumab-Induced Reactivation of Hepatitis B. Case Rep Oncol Med,2018,2018:5985131.
[21] Katoonizadeh A,Motamed-Gorji N,Sharafkhah M,et al.Intra-familial Transmission of Chronic Hepatitis B Infection:A Large Population-Based Cohort Study in Northern Iran. Arch Iran Med, 2018,21(10):436-442.

Changes of peripheral blood CD8⁺CD28⁺T lymphocyte percentages in patients with hepatitis B

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[2]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[3]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[4]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[5]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[6]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[7]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[8]	Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 613-616.
[9]	Liao Guichan, Peng Jie, Zhang Xiaoyong. Roles of hepatocytes in intrinsic innate immunity in control of hepatits B virus infection [J]. Journal of Practical Hepatology, 2019, 22(5): 617-619.
[10]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[11]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.
[12]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[13]	Zhu Yucheng, Yan Jiawei, Sun Jingkun, et al. Serum diamine oxidase level in patients with hepatitis B-induced acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2019, 22(5): 672-675.
[14]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.
[15]	Bai Yichun, Deng Jihong, Mei Xiaoping. Efficacy of peginterferon alfa-2b treatment and affecting response factors in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 490-493.

Changes of peripheral blood CD8+CD28+T lymphocyte percentages in patients with hepatitis B

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

Changes of peripheral blood CD8⁺CD28⁺T lymphocyte percentages in patients with hepatitis B